sotigalimab + carboplatin + paclitaxel

This is an investigational triplet drug combination consisting of sotigalimab, carboplatin, and paclitaxel. **Sotigalimab** is a monoclonal antibody targeting CD40, functioning as an agonist to activate antigen-presenting cells and enhance antitumor immune response. **Carboplatin** is a platinum-based chemotherapeutic agent that induces DNA crosslinking, leading to apoptosis in rapidly dividing cancer cells. **Paclitaxel** is a taxane-based chemotherapeutic agent that stabilizes microtubules and inhibits cell division. The combination aims to provide synergistic antitumor activity by combining immune activation with cytotoxic chemotherapy.